[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurexone Biologic Inc (NRXBF)

Nurexone Biologic Inc (NRXBF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 36,818
  • Shares Outstanding, K 92,046
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,380 K
  • EBIT $ -5 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 18.39
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.02 on 06/01/26
  • Next Earnings Date 08/26/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3671 +8.96%
on 06/15/26
0.4733 -15.49%
on 05/29/26
-0.0655 (-14.07%)
since 05/26/26
3-Month
0.3671 +8.96%
on 06/15/26
0.4835 -17.27%
on 05/20/26
-0.0193 (-4.60%)
since 03/25/26
52-Week
0.3671 +8.96%
on 06/15/26
0.8000 -50.00%
on 09/16/25
-0.1134 (-22.09%)
since 06/25/25

Most Recent Stories

More News
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”)...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90)  (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.570 (+1.79%)
NRXBF : 0.4000 (+0.40%)

Business Summary

NurExone Biologic Inc. is a pharmaceutical company which involved in developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's principal product includes ExoPTEN. NurExone Biologic...

See More

Key Turning Points

3rd Resistance Point 0.4000
2nd Resistance Point 0.4000
1st Resistance Point 0.4000
Last Price 0.4000
1st Support Level 0.4000
2nd Support Level 0.4000
3rd Support Level 0.4000

See More

52-Week High 0.8000
Fibonacci 61.8% 0.6346
Fibonacci 50% 0.5835
Fibonacci 38.2% 0.5325
Last Price 0.4000
52-Week Low 0.3671

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.